Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
Authors:
Open Access
- 1 March 1993
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 90 (5) , 1882-1886
Abstract
Transmission studies have suggested that an optimal human immunodeficiency virus type 1 (HIV-1) vaccine should induce both neutralizing antibodies and cytolytic T cells to eliminate free virus and infected cells. A phase I trial in healthy HIV-1-seronegative persons was conducted with a combination HIV-1 vaccine regimen (strain IIIB) consisting of priming with a recombinant vaccinia (vac/env) virus expressing HIV-1 envelope and boosting with a gp160 glycoprotein derived from a recombinant baculovirus (rgp160). T-cell and antibody responses detected after immunization with either vac/env alone or rgp160 alone were generally of low magnitude and transient, and no subject developed neutralizing antibodies. In contrast, recipients of the combination regimen demonstrated in vitro T-cell proliferative responses to homologous HIV-1 antigens that were 3- to 10-fold higher than responses with either vaccine alone, and these responses were sustained for > 18 months in 75% of recipients. Moreover, both CD8+ and CD4+ cytolytic T cells were detected. Antibody responses (titer, 1:800 to 1:102,400) to homologous HIV envelope developed in all recipients of the combination regimen, and neutralizing antibodies were detected in 7 of 13. Thus, immunization with a live virus vaccine followed by boosting with a soluble protein offers promise for inducing the broad immunity needed in an HIV vaccine.Keywords
This publication has 22 references indexed in Scilit:
- An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells.Journal of Experimental Medicine, 1990
- Induction of CD4 + Human Cytolytic T Cells Specific for HIV-Infected Cells by a Gp160 Subunit VaccineScience, 1990
- Lymphoproliferative Responses to Mitogens and HIV-1 Envelope Glycoprotein Among Volunteers Vaccinated with Recombinant gp160AIDS Research and Human Retroviruses, 1990
- The Persistence of Neutralizing Antibodies after Revaccination against SmallpoxThe Journal of Infectious Diseases, 1990
- Poxvirus-based vectors as vaccine candidates.1990
- Plasma Viremia in Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1989
- Antigen form influences induction and frequency of influenza-specific class I and class II MHC-restricted cytolytic T lymphocytes.The Journal of Immunology, 1988
- A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDSNature, 1988
- Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins.The Journal of Immunology, 1987
- Vaccinia Virus Expression VectorsAnnual Review of Immunology, 1987